Sharps Technology settles litigation, transfers Safegard Medical Kft assets

Sharps Technology Inc.

Signed confidential settlement on Oct 6, 2025 with Barry Berler, Plastomold and affiliates, resolving all litigation claims.
Will transfer all shares of Hungarian subsidiary Safegard Medical Kft and certain patents/trademarks to Plasto Technology.
Pro forma H1 2025 revenue decreases from $222.7K to $136.1K; total assets drop from $17.1M to $9.5M.
Divestiture removes $889.6K of inventory and $4.3M of fixed assets from balance sheet.
Accumulated deficit increases by $6.5M to $35.5M due to net impact of divestiture.

item 1.01 item 2.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-017032
form_type: 8-K
ticker: STSS
cik: 0001737995
company_name: Sharps Technology Inc.
filed_at: 2025-10-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.284561+00:00
generated_at: 2026-05-17T04:36:24.180343+00:00
sec_items: ["1.01", "2.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-017032
json_url: https://secwatch.observer/filing/0001493152-25-017032.json
markdown_url: https://secwatch.observer/filing/0001493152-25-017032.md
text_url: https://secwatch.observer/filing/0001493152-25-017032.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315225017032/0001493152-25-017032-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1737995/000149315225017032/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-017032

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.